Caitlin Raymond: Understanding Risks in Rare Group A Subtypes with Anti-A1 Antibodies in Transfusion Medicine
Caitlin Raymond, Assistant Professor of Pathology and Transfusion Medicine at the University of Wisconsin-Madison, shared a post on LinkedIn:
”In transfusion medicine, some risks feel larger than they actually are — not because they’re common, but because the evidence we have is skewed toward worst-case scenarios.
I recently wrote a follow-up blog post on rare group A subtypes with anti-A1 antibodies, prompted by a real case and a conversation with a reference laboratory.
Case reports tell us what can go wrong. Reference labs see what actually does go wrong — and how often.
This post walks through:
- When cold reacting anti-A1 actually becomes dangerous
- Why malignancy-associated cases don’t generalize
- When to choose group O blood for rare group A subtypes
If you’ve ever felt uneasy making decisions where the literature offers warnings but no denominator, this one’s for you.”
Stay updated with Hemostasis Today.
-
Jun 23, 2026, 18:27Advancing Gene Therapy Research for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jun 23, 2026, 18:17What Every ITP Patient Wants to Know – ITP Support Association
-
Jun 23, 2026, 18:13Ahsan Fareed: Exploring Heart Failure Readmissions in Iron Deficiency Anemia
-
Jun 23, 2026, 18:09Swarnava Roy: Key Findings on Stress Erythropoiesis and Mitochondrial Retention in RBCs
-
Jun 23, 2026, 17:40Hossam El Benawi: How do We Predict Recurrence Post LVT Resoultion?
-
Jun 23, 2026, 17:39Nicolas Gendron: Do We Really Need All These Hemostasis Tests in Patients on DOACs?
-
Jun 23, 2026, 17:33Maité Mulkers: Time is Brain, and One Reason is That a Thrombus Develops Over Time
-
Jun 23, 2026, 17:32Dhargam Aljebouri: Honoured to Be Part of the Young Professionals Breakfast at ISBT 2026
-
Jun 23, 2026, 17:27Dianne E. van der Wal: Phenotype and Activation of the Endothelium in ET at ISTH 2026